Glucuronomannan GM2 from <i>Saccharina japonica</i> Enhanced Mitochondrial Function and Autophagy in a Parkinson’s Model

• Main Authors: Yingjuan Liu, Weihua Jin, Zhenzhen Deng, Quanbin Zhang, Jing Wang
• Format: Article
• Language: English
• Published: MDPI AG 2021-01-01
• Series: Marine Drugs
• Subjects: glucuronomannan oligosaccharide; Parkinson’s disease; apoptosis; autophagy; mitochondria
• Online Access: https://www.mdpi.com/1660-3397/19/2/58

Parkinson’s disease (PD), one of the most common neurodegenerative disorders, is caused by dopamine depletion in the striatum and dopaminergic neuron degeneration in the substantia nigra. In our previous study, we hydrolyzed the fucoidan from <i>Saccharina japonica</i>, obtaining three glucuronomannan oligosaccharides (GMn; GM1, GM2, and GM3) and found that GMn ameliorated behavioral deficits in Parkinsonism mice and downregulated the apoptotic signaling pathway, especially with GM2 showing a more effective role in neuroprotection. However, the neuroprotective mechanism is unclear. Therefore, in this study, we aimed to assess the neuroprotective effects of GM2 in vivo and in vitro. We applied GM2 in 1-methyl-4-phenylpyridinium (MPP⁺)-treated PC12 cells, and the results showed that GM2 markedly improved the cell viability and mitochondrial membrane potential, inhibited MPP⁺-induced apoptosis, and enhanced autophagy. Furthermore, GM2 contributed to reducing the loss of dopaminergic neurons in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice through enhancing autophagy. These data indicate that a possible protection of mitochondria and upregulation of autophagy might underlie the observed neuroprotective effects, suggesting that GM2 has potential as a promising multifunctional lead disease-modifying therapy for PD. These findings might pave the way for additional treatment strategies utilizing carbohydrate drugs in PD.